Which is the most valuable treatment for recurrent in-stent restenosis, namely the ISR of 2 already implanted stents? We investigated the role of drug-coated balloons in this setting, and our findings seem to show how this strategy should be considered.
The role of DCB for recurrent ISR
BVS SAVE: The BVS-SAVE Italian registry: Bioresorbable Vascular Scaffolds for the Treatment of Small Vessel Disease
Much debate is currently running on BVS performance in small coronary vessels. I am here attaching one of the few publications available worldwide, that our group coordinated recently: the BVS SAVE study. This poster was presented at both the 2015 GISE and TCT meetings. Please take a look at the results.
International Consensus on DCB use for Peripheral Interventions
A few months ago, an expert panel lead by our group published the International Positioning Document on DCB use in peripheral interventions. The document was published in the European Heart Journal.
Bivalirudin use-an update after the Matrix trial
This is the presentation I had at the CCIF meeting at Guiyang, China, April 2015.
Which is the current role of Bivalirudin in ACS patients, nowadays? Did the Matrix trial change the scenario, or created more confusion on the matter?
BVS Survey 2014
This is the PPTX presentation of the BVS survey 2014, as presented at the BVS Advisory Board of Abbott in March 2015. This is a spontaneous survey dedicated to BVS Expert Users, and I shared this research with M. Valgimigli, Bern.
It is of some interest to see how Experts felt this technology by mid-2014, and a publication in the International Journal of Cardiology followed. Another Survey was depicted in 2015 and we are currently analyzing its results.
I am thus wishing you all a happy New Year!!